綠葉製藥(02186.HK):力撲素®列入新版國家醫保目錄
格隆匯 12 月 28日丨綠葉製藥(02186.HK)宣佈,集團的創新紫杉醇脂質體制劑—力撲素®被列入新版國家醫保目錄("國家醫保目錄")乙類範圍。力撲素®説明書所有適應症,包括非小細胞肺癌、卵巢癌和乳腺癌都已獲得國家醫保報銷。
力撲素®為集團的專利製備紫杉醇類製劑,運用創新的脂質體給藥劑,用於非小細胞肺癌、卵巢癌、乳腺癌等若干類癌症的化學治療。集團在中國持有紫杉醇脂質體的組成和配方專利。於公吿日期,力撲素®為全球首個及中國唯一獲批准銷售的紫杉醇脂質體產品。
根據IQVIA的資料,力撲素®為2020年上半年中國第二大的國內抗癌藥品,同時亦為2020年上半年中國最普遍採用的紫杉醇類產品。此前,紫杉醇脂質體已作為一線藥物被寫入《CSCO乳腺癌診療指南(2020版)》、《CSCO原發性肺癌診療指南(2019版)》、並被納入《婦科惡性腫瘤紫杉類藥物臨牀應用專家共識》、《乳腺癌中紫杉類藥物臨牀應用專家共識(2020年)》中。此外,紫杉醇脂質體還作為多項放化療首選聯合用藥入選《中國食管癌放射治療指南(2019版)》。
董事會相信,力撲素®被納入新版國家醫保目錄證明其符合國家醫療保障局對藥品的的臨牀價值、對患者帶來益處、創新程度等方面的認可,將令更多患者能夠負擔得起力撲素®,提升該產品在相關適應症上的滲透率,為力撲素®的長期增長注入動力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.